KCT0005358招募中未知
A Multi-center, Randomized, Double-Blind, Phase II clinical trial to Evaluate the Efficacy and Safety of 12-week treatment of ALH-L1005 600 mg or 1200 mg in Patients with Chronic Periodontitis
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- AngioLab
- 入组人数
- 117
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 78(Year)（—）
- 性别
- All
入选标准
- •Men or women ages 18 and over, under 79 years of age
- •Patients diagnosed with chronic periodontitis
- •Patients with 4 teeth and over whose pocket depth is = 4 mm and clinical attachment level is = 3 mm
- •Patients who are voluntarily participated in clinical trial
排除标准
- •History of antibiotic therapy within the 1 month prior to study
- •Those who had undergone any dental surgical or non-surgical therapy within 3 months prior to the start of the study
- •Subjects who are pregnant/ lactating
- •Patients who take Anticoagulants or Antiplatelet Agents
- •With Systemic diseases that affect periodontal conditions such as: diabetes, hypertension and diseases of immune system
研究者
相似试验
进行中（未招募）
1 期
Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib in Subjects with advanced liver cancerunresectable advanced hepatocellular carcinomaMedDRA version: 21.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2019-003337-41-ESCStone Pharmaceuticals (Suzhou) Co., Ltd.525
进行中（未招募）
1 期
Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib in Subjects with advanced liver cancerEUCTR2019-003337-41-ITCStone Pharmaceuticals (Suzhou) Co., Ltd.525
进行中（未招募）
1 期
Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib in Subjects with advanced liver cancerEUCTR2019-003337-41-PLCStone Pharmaceuticals (Suzhou) Co., Ltd.534
进行中（未招募）
3 期
A Phase III Study to check the Safety and efficacy of the PCV 13 Vaccine in Healthy Infants in India in prevention of Pneumococcal disease caused by Streptococcus pneumonia.CTRI/2022/11/047443G C Chemie Pharmie Ltd
进行中（未招募）
不适用
A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV MelanomaRevised Protocol 1, incorporating Amendment 2 - version 4.0, dated 15-Feb-06Previously treated unresectable Stage III or IV MelanomaEUCTR2005-003265-16-BEBristol-Myers Squibb International Corporation240